Psoriatic Arthritis
Women with psoriatic arthritis report worse outcomes, treatment response vs. men
There are key sex-specific differences in how psoriatic arthritis manifests in patients, with women reporting worse outcomes and treatment response compared with men, according to a review published in The Journal of Rheumatology.
‘A little bit unique’: Consider every SAPHO manifestation when examining patients
SCOTTSDALE, Ariz. — SAPHO is complex, but knowing its potential manifestations can help clinicians identify and help patients, according to a speaker at the Basic and Clinical Immunology for the Busy Clinician meeting.
Patients’ priorities, individual burden should guide psoriatic arthritis treatment
SCOTTSDALE, Ariz. — Understanding patients’ disease burden and priorities can help rheumatologists choose the best therapy for psoriatic arthritis, noted a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.
Guselkumab’s safety profile consistent regardless of TNF-inhibitor use in psoriatic arthritis
The 2-year safety profile of guselkumab appears consistently favorable across patients with psoriatic arthritis who are either naïve or experienced with TNF inhibitors, according to data published by The Journal of Rheumatology.
Guselkumab improves PsA symptoms in 6-month real-world study
WAILEA, Hawaii — Patients with psoriatic arthritis treated with guselkumab for 6 months experienced a significant improvement in joint disease, skin disease and pain, according to a poster presented at the Maui Derm meeting.
Ustekinumab, TNF inhibitors exhibit comparable 3-year persistence in psoriatic arthritis
Ustekinumab and TNF inhibitors demonstrate comparably persistent effects at 3 years in patients with psoriatic arthritis, but with fewer adverse events in those receiving ustekinumab, according to data.
Baseline radiographic damage prevalence ‘substantial’ in psoriatic arthritis
Patients with psoriatic arthritis demonstrate a “substantial prevalence” of radiographic damage at baseline, which is related to time since diagnosis, according to data published in Arthritis Research and Therapy.
Risankizumab improves symptoms, is well tolerated in psoriatic arthritis through 52 weeks
Risankizumab improves symptoms and is well tolerated through 52 weeks in patients with psoriatic arthritis who respond inadequately to biologic therapies or conventional synthetic disease-modifying antirheumatic drugs, according to data.
Healthy diet may improve measures of disease activity in psoriatic arthritis
PHILADELPHIA — While a high prevalence of metabolic disorders was observed among patients with psoriatic arthritis, measures of disease activity was associated with adherence to healthy diet recommendations, such as low sugar and whole-fruit consumption.
Clinical response in PsA meaningful captured by treat-to-target metrics
PHILADELPHIA — Patients with psoriatic arthritis who achieved clinical disease control demonstrated clinically meaningful improvements across a broad range of patient-reported outcomes, including pain, fatigue, physical function and work productivity.